Rumunsko - rumunčina - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

solupharm pharmazeutische erzeugnisse gmbh - germania - dobutaminum - sol. perf. - 250mg - stimulante cardiace excl. glicozizi cardiotonici med.adrenergice si dopaminergice

Európska únia - rumunčina - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccinuri - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. utilizarea acestui vaccin ar trebui să fie în conformitate cu recomandările oficiale.

Európska únia - rumunčina - EMA (European Medicines Agency)

pacira limited - citarabină - meningeal neoplasme - agenți antineoplazici - tratamentul intrathecal al meningitei limfomatoase. În majoritatea pacienților, un astfel de tratament va face parte din paliația simptomatică a bolii.

Moldavsko - rumunčina - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

atnahs pharma uk ltd. - acid ibandronicum - comprimate filmate - 150 mg

Európska únia - rumunčina - EMA (European Medicines Agency)

mylan pharmaceuticals limited - clorhidratul de anagrelidă - trombocitmie, esențială - agenți antineoplazici - anagrelidă este indicat pentru reducerea numărului crescut de trombocite în risc de trombocitemie esențială (te) pacienții care nu tolerează terapia curentă sau a căror crescut de trombocite nu sunt reduse la un nivel acceptabil prin lor actuale de terapie. an at-risk patientan at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10⁹/l ora history of thrombo-haemorrhagic events.

Rumunsko - rumunčina - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

farmasierra manufacturing s.l. - spania - ibuprofenum - susp. orala - 20mg/ml - antiinflamatoare si antireumatice nesteroidiene derivati de acid propionic

Rumunsko - rumunčina - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

biofabri, s.l. - spania - ibuprofenum - susp. orala in plic - 100mg - antiinflamatoare si antireumatice nesteroidiene derivati de acid propionic

Rumunsko - rumunčina - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

biofabri, s.l. - spania - ibuprofenum - susp. orala in plic - 200mg - antiinflamatoare si antireumatice nesteroidiene derivati de acid propionic

Rumunsko - rumunčina - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

biofabri, s.l. - spania - ibuprofenum - susp. orala in plic - 400mg - antiinflamatoare si antireumatice nesteroidiene derivati de acid propionic

Moldavsko - rumunčina - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

engelhard arzneimittel gmbh&co.kg - ivy helix - picături orale, soluţie - 20 mg/ml